1. Home
  2. PAMT vs ZBIO Comparison

PAMT vs ZBIO Comparison

Compare PAMT & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAMT
  • ZBIO
  • Stock Information
  • Founded
  • PAMT 1980
  • ZBIO 2019
  • Country
  • PAMT United States
  • ZBIO United States
  • Employees
  • PAMT N/A
  • ZBIO N/A
  • Industry
  • PAMT Trucking Freight/Courier Services
  • ZBIO
  • Sector
  • PAMT Industrials
  • ZBIO
  • Exchange
  • PAMT Nasdaq
  • ZBIO NYSE
  • Market Cap
  • PAMT 356.4M
  • ZBIO 339.3M
  • IPO Year
  • PAMT 1985
  • ZBIO 2024
  • Fundamental
  • Price
  • PAMT $16.64
  • ZBIO $7.85
  • Analyst Decision
  • PAMT
  • ZBIO Strong Buy
  • Analyst Count
  • PAMT 0
  • ZBIO 5
  • Target Price
  • PAMT N/A
  • ZBIO $31.75
  • AVG Volume (30 Days)
  • PAMT 42.0K
  • ZBIO 390.2K
  • Earning Date
  • PAMT 01-30-2025
  • ZBIO 02-16-2025
  • Dividend Yield
  • PAMT N/A
  • ZBIO N/A
  • EPS Growth
  • PAMT N/A
  • ZBIO N/A
  • EPS
  • PAMT N/A
  • ZBIO N/A
  • Revenue
  • PAMT $728,284,000.00
  • ZBIO N/A
  • Revenue This Year
  • PAMT N/A
  • ZBIO N/A
  • Revenue Next Year
  • PAMT $4.86
  • ZBIO N/A
  • P/E Ratio
  • PAMT N/A
  • ZBIO N/A
  • Revenue Growth
  • PAMT N/A
  • ZBIO N/A
  • 52 Week Low
  • PAMT $13.51
  • ZBIO $7.50
  • 52 Week High
  • PAMT $23.70
  • ZBIO $26.25
  • Technical
  • Relative Strength Index (RSI)
  • PAMT N/A
  • ZBIO N/A
  • Support Level
  • PAMT N/A
  • ZBIO N/A
  • Resistance Level
  • PAMT N/A
  • ZBIO N/A
  • Average True Range (ATR)
  • PAMT 0.00
  • ZBIO 0.00
  • MACD
  • PAMT 0.00
  • ZBIO 0.00
  • Stochastic Oscillator
  • PAMT 0.00
  • ZBIO 0.00

About PAMT PAMT CORP Common Stock

PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec.

About ZBIO ZENAS BIOPHARMA INC

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Share on Social Networks: